A systematic review of Bisphenol A “low dose” studies in the context of human exposure: A case for establishing standards for reporting “low-dose” effects of chemicals

Teeguarden, Justin G.; Hanson-Drury, Sesha

doi:10.1016/j.fct.2013.07.007

Cited by 87 publications

(55 citation statements)

References 252 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…6 Yet, because studies estimate human exposures from dietary sources in the range of 0.1-5 μg/kg body weight/day, 154 there have been suggestions that only studies examining exposures in this range should be considered "low dose." 155 Importantly, many significant effects are observed following administration of doses below the EPA reference dose of 50 μg/ kg body weight/day, and some of these studies show effects in the range of estimated human exposures (≤ 5 μg/kg body weight/ day). 118,124,126,130,132,133,135,136,141,143,150,152, Previous reviews have also noted a relatively large number of studies that demonstrated effects in the range of human exposures from dietary sources.…”

Section: -53mentioning

confidence: 99%

Low dose effects of bisphenol A

Vandenberg

Ehrlich

Belcher

et al. 2013

Endocrine Disruptors

182

View full text Add to dashboard Cite

Section: -53mentioning

confidence: 99%

Low dose effects of bisphenol A

Vandenberg

Ehrlich

Belcher

et al. 2013

Endocrine Disruptors

182

View full text Add to dashboard Cite

“…The population may be exposed to BPA from fetal life to adulthood (Cobellis et al, 2009;Vandenberg et al, 2010;Braun and Hauser, 2011;Koch et al, 2012). Many reports claim that it belongs to the growing list of so-called endocrine-disrupting chemicals (EDC; Beronius et al, 2010;Teeguarden and Hanson-Drury, 2013). Decision of a number of regulatory agencies to ban BPA from food packaging has led to the gradual development of a number of bisphenol analogs (BPA-A) to replace BPA in several applications.…”

Section: Introductionmentioning

confidence: 99%

Parallel assessment of the effects of bisphenol A and several of its analogs on the adult human testis

et al. 2017

View full text Add to dashboard Cite

WHAT IS KNOWN ALREADY:The few epidemiologic studies performed suggest that bisphenols have potential endocrine disruptive properties, but they did not identify clear and direct patterns of endocrine disruption. STUDY DESIGN, SIZE, DURATION:Adult human testis explants in culture were exposed to BPA and the analogs bisphenol F (BPF), bisphenol S (BPS), bisphenol E (BPE), bisphenol B (BPB), and bisphenol A diglycidyl ether (BADGE) at 10 -9 to 10 -5 M for 24 h or 48h.PARTICIPANTS/MATERIALS, SETTING, METHODS: Human adult testes were obtained from prostate cancer patients who had no hormone therapy, or from multiorgan donors. After ex vivo exposure to the investigated bisphenols, the measured outcomes were related to histopathology (gross morphology and germ cell viability determined by anti-caspase 3 immunohistochemistry), and the levels of testosterone, insulin-like fator 3 and inhibin B were measured using immunoassays. The levels of mRNA encoding key enzymes of bisphenol biotransformation were investigated by quantitative PCR: UGT2B15 UDP (glucuronosyltransferase two family, polypeptide B15), GUSB (glucuronidase beta), SULT1A1 and 3 (sulfotransferase family 1 A member 1 and 3) and STS (steroid sulfatase). MAIN RESULTS AND THE ROLE OF CHANCE: A significant dose-dependent inhibition wasfound between testosterone levels measured in the culture medium and concentrations of BPA The active concentrations of BPA and BPA-A used in the study were higher than those found in human biological fluids. WIDER IMPLICATIONS OF THE FINDINGS:Under our experimental conditions, direct exposure to BPA or BPA-A can result in endocrine disturbance in the adult human testis.

show abstract

“…On the one hand, there has been increasing concern about the potential impact of BPA on human health (Rochester, 2013;Teegarden and Drury, 2013). Public concern was amplified by recent studies showing relationships between BPA exposure and obesity (Wang et al, 2012), cardiovascular disease (Melzer et al, 2010), behaviour (Braun et al, 2010), and birth outcomes (Lee et al, 2013).…”

Section: The Making Of the Controversymentioning

confidence: 99%

Looking back and going forward: what should the new European Commission do in order to promote evidence-based policy-making?

Löfstedt

Schlag

2016

Journal of Risk Research

View full text Add to dashboard Cite

In this paper we first give an overview of what has happened in Europe within the area of regulation over the past 5 years or so. We then examine where the new European Commission and the Parliament are with regard to evidencebased and risk-informed policy making taking a specific look at the importance of transparency among European regulatory agencies, the calls for better regulation that were initiated by First Vice President Timmermans, and the continued miss-use of the precautionary principle. In the final section we provide a number of recommendations on what the Commission and the Parliament should do going forward including moving away from fish bowl to science based transparency, making the member states more receptive to science based policy making and strengthening the capacity of the European Commission to further promote evidence-based and risk-informed policy making.

show abstract

A systematic review of Bisphenol A “low dose” studies in the context of human exposure: A case for establishing standards for reporting “low-dose” effects of chemicals

Cited by 87 publications

References 252 publications

Low dose effects of bisphenol A

Low dose effects of bisphenol A

Parallel assessment of the effects of bisphenol A and several of its analogs on the adult human testis

Looking back and going forward: what should the new European Commission do in order to promote evidence-based policy-making?

Contact Info

Product

Resources

About